Efficacy News and Research

RSS
BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

G-CSF treatment improves inadequate endometrium during IVF cycles

G-CSF treatment improves inadequate endometrium during IVF cycles

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

New vaccine offers hope against Hepatitis C

New vaccine offers hope against Hepatitis C

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept 2010 fourth quarter net loss is $0.06 per share

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Diabetes technology granted patent in Australia

Diabetes technology granted patent in Australia

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Antiepileptic drugs could make HIV drugs less effective

Antiepileptic drugs could make HIV drugs less effective

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Cerasome filled molecular-sized bubbles to target liver cancer cells

Cerasome filled molecular-sized bubbles to target liver cancer cells

Tifacogin administration shows no treatment benefit in patients with severe CAP

Tifacogin administration shows no treatment benefit in patients with severe CAP

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.